# Trading Cycle Report - 2026-06-11

**Environment**: staging
**Cycle covered**: runs 665-668
**Cycle triggered**: manual at 2026-06-11 05:08:10 UTC (via `POST /api/trigger-cycle` on `agents-697cb74b98-5szvj`, internal port 8000)
**Cycle duration**: ~1m 41s (05:08:10 → 05:09:51)
**Overall result**: 4/4 completed, 4 trades executed, 0 HOLD, 0 failed

---

## Cycle Summary — 2026-06-11 05:08 UTC

| Agent  | Style              | Decision | Symbol | Qty | Price     | Total      | Candidates                  |
|--------|--------------------|----------|--------|-----|-----------|------------|-----------------------------|
| George | Contrarian Macro   | SELL     | ALB    | 39  | $147.22   | $5,741.58  | NEM, CAT, INTC, LNG         |
| Warren | Value Investor     | BUY      | PG     | 41  | $149.05   | $6,111.05  | CSCO, PG, KO                |
| Cathie | Growth Innovation  | SELL     | SNOW   | 34  | $239.90   | $8,156.60  | MBLY, RIVN, COIN, ILMN      |
| Ray    | Risk Parity        | BUY      | PG     | 42  | $149.05   | $6,260.10  | PG, KO, JNJ                 |

---

## Portfolio Snapshots (Latest)

| Agent  | Cash       | Holdings Value | Total Value  | Total P&L     | Return %   |
|--------|------------|----------------|--------------|---------------|------------|
| Warren | $35,462.25 | $74,441.40     | $109,903.65  | +$9,903.65    | +9.90%     |
| George | $37,620.73 | $61,179.73     | $98,800.46   | -$1,199.54    | -1.20%     |
| Ray    | $35,993.88 | $62,382.68     | $98,376.56   | -$1,623.44    | -1.62%     |
| Cathie | $32,018.73 | $89,090.11     | $121,108.84  | +$21,108.84   | +21.11%    |

**Combined portfolio**: $428,189.51 · **Combined P&L**: +$28,189.51 (+7.05% blended return).

---

## Guardrail Columns Sanity-Check (V2/V3 Audit)

Per-phase guardrail-column population across all 8 phase rows (4 research + 4 decision) for runs 665-668:

| Run | Phase    | guardrail_attempts | guardrail_outcome | guardrail_issues | guardrail_failed_output |
|-----|----------|-------------------:|-------------------|------------------|-------------------------|
| 665 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 665 | decision | 1                  | `first_try`       | NULL             | NULL                    |
| 666 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 666 | decision | 1                  | `first_try`       | NULL             | NULL                    |
| 667 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 667 | decision | 1                  | `first_try`       | NULL             | NULL                    |
| 668 | research | 1                  | `first_try`       | NULL             | NULL                    |
| 668 | decision | 1                  | `first_try`       | NULL             | NULL                    |

**Verdict**: PASS — 8/8 phase rows clean. All `guardrail_attempts=1`, all `guardrail_outcome='first_try'`, all `guardrail_issues=NULL`, all `guardrail_failed_output=NULL`. The V2/V3 persistence path is populating correctly end-to-end after the backend redeploy.

---

## Current Holdings

### Warren (10 positions)
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ADP    | 29  | $218.35   | $6,332.15   |
| BRK.B  | 36  | $479.95   | $17,278.22  |
| JNJ    | 26  | $230.69   | $5,997.94   |
| LMT    | 12  | $520.07   | $6,240.84   |
| MCD    | 19  | $301.84   | $5,734.96   |
| MRK    | 63  | $111.92   | $7,050.96   |
| MSFT   | 18  | $420.77   | $7,573.86   |
| ORCL   | 26  | $232.28   | $6,039.28   |
| PG     | 41  | $149.05   | $6,111.05   |
| V      | 20  | $322.52   | $6,450.40   |

### George (9 positions)
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| CCJ    | 77  | $105.44   | $8,118.88   |
| CF     | 58  | $114.40   | $6,635.20   |
| FCX    | 97  | $70.64    | $6,852.08   |
| FNV    | 30  | $225.38   | $6,761.40   |
| KMI    | 219 | $31.08    | $6,806.52   |
| LMT    | 15  | $530.13   | $7,951.95   |
| MP     | 98  | $69.29    | $6,790.42   |
| NTR    | 122 | $65.03    | $7,933.66   |
| XOM    | 48  | $147.90   | $7,099.20   |

### Ray (10 positions)
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ADP    | 28  | $218.35   | $6,113.80   |
| ATO    | 40  | $187.26   | $7,490.40   |
| DUK    | 51  | $124.22   | $6,335.22   |
| MDT    | 72  | $83.32    | $5,999.04   |
| O      | 106 | $59.91    | $6,350.46   |
| PG     | 42  | $149.05   | $6,260.10   |
| TRV    | 20  | $301.53   | $6,030.60   |
| VZ     | 132 | $47.97    | $6,332.04   |
| WM     | 25  | $228.77   | $5,719.25   |
| WMT    | 52  | $120.72   | $6,277.44   |

### Cathie (9 positions)
| Symbol | Qty | Avg Price | Cost Basis  |
|--------|-----|-----------|-------------|
| ARM    | 31  | $213.27   | $6,611.37   |
| ASML   | 4   | $1,478.41 | $5,913.64   |
| CRWD   | 10  | $731.00   | $7,310.00   |
| DDOG   | 36  | $227.34   | $8,184.24   |
| GOOGL  | 33  | $318.28   | $10,503.24  |
| MRVL   | 27  | $316.43   | $8,543.61   |
| MSFT   | 11  | $424.62   | $4,670.82   |
| NVDA   | 135 | $183.91   | $24,827.85  |
| PLTR   | 61  | $130.21   | $7,942.81   |

---

## Detailed Run Data

### Run 665: George (Contrarian Macro)

**Started**: 2026-06-11 05:08:10 UTC | **Completed**: 2026-06-11 05:09:39 UTC
**Status**: COMPLETED

#### Research Phase (51,593 ms)
**Candidates**: NEM, CAT, INTC, LNG

**Tool Calls** (9):
1. `brave_web_search(query="contrarian macro stock picks 2026 gold Newmont NEM Intel INTC Caterpillar CAT Cheniere LNG macro trends dollar rates 2026", count=10)`
2. `brave_web_search(query="Newmont NEM news June 2026 gold outlook 2026 Newmont quarterly 2026 news", count=10)`
3. `brave_web_search(query="Caterpillar CAT June 2026 outlook infrastructure demand China reopening 2026 Caterpillar news June 2026", count=10)`
4. `brave_web_search(query="Intel INTC 2026 turnaround wafer fabs 'contrarian' 2026 news May June 2026 Intel earnings 2026 article", count=10)`
5. `brave_web_search(query="Cheniere Energy LNG stock ticker Cheniere Energy 2026 outlook LNG demand Europe 2026 news June 2026 Cheniere LNG NYSE", count=10)`
6. `lookup_price_tool(symbol="NEM")`
7. `lookup_price_tool(symbol="CAT")`
8. `lookup_price_tool(symbol="INTC")`
9. `lookup_price_tool(symbol="LNG")`

**Research Notes**:
> Macro thesis: With markets bifurcating between commodity/capex reflation and an AI-driven tech rotation, I picked a small, contrarian basket to diversify away from the current materials-heavy book while keeping exposure to commodity/energy dislocations and a high-conviction tech turnaround. Newmont (NEM) is a hedge against macro uncertainty and inflation-sensitive upside if gold re-accumulates; Cheniere (LNG) is a geopolitically exposed LNG exporter benefitting from structurally tight global gas markets and long-term offtake contracts; Caterpillar (CAT) captures a potentially underappreciated industrial capex cycle tied to mining, infrastructure and data-center power demand; Intel (INTC) is a contrarian semiconductor turnaround play—cheap relative to the AI winners and levered to reshoring/foundry wins if its 18A/14A ramps sustain.
>
> These names provide asymmetric payoffs relative to the current holdings: they hedge different macro outcomes (safe-haven/commodity risk, energy security, industrial capex, and tech/sovereign supply-chain reshoring) while offering opportunities to replace/or re-balance existing commodity concentration if needed.

**Web Sources**:
- [Newmont Generates Record Quarterly Earnings and Free Cash Flow](https://www.newmont.com/investors/news-release/news-details/2026/Newmont-Generates-Record-Quarterly-Earnings-and-Free-Cash-Flow-Reports-First-Quarter-2026-Results-and-Announces-Increased-Share-Repurchase-Authorization/default.aspx)
- [Newmont Corporation (NEM) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/NEM/)
- [Caterpillar (CAT) Stock Price & Overview](https://stockanalysis.com/stocks/cat/)
- [How Investors Are Reacting To Caterpillar (CAT) AI Data Center Demand](https://simplywall.st/stocks/us/capital-goods/nyse-cat/caterpillar/news/how-investors-are-reacting-to-caterpillar-cat-ai-data-center-1)
- [Intel Reports First-Quarter 2026 Financial Results](https://www.intc.com/news-events/press-releases/detail/1767/intel-reports-first-quarter-2026-financial-results)
- [Intel (INTC) Q1 2026 earnings report - CNBC](https://www.cnbc.com/2026/04/23/intel-intc-q1-2026-earnings-report.html)
- [Cheniere Energy, Inc. | Quote](https://lngir.cheniere.com/stock-data/quote)
- [Cheniere Energy, Inc. (LNG) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/LNG/)

**Portfolio Context**: Balance $31,879.15, 10 positions (LMT, XOM, FNV, NTR, KMI, CF, MP, ALB, FCX, CCJ).

#### Decision Phase (30,587 ms)
**Decision**: SELL ALB x39

**Reasoning**:
- **Research**: Market Analyst candidates: NEM ($92.77; Newmont press release shows record FCF — NEM cited historically ~high-teens to low-20s P/E in prior notes), CAT ($856.16), INTC ($107.04), LNG ($241.81). Analyst flagged sector valuations: SCCO TTM P/E ≈28.7 (producer multiple premium) and noted ALB/Lithium faces near-term oversupply commentary despite improving demand signals. Selling ALB (current holding ~39 @ ~$171–179) reduces single-theme commodity risk and preserves optionality to buy a contrarian hedge: e.g., NEM at $92.77 (~68 shares ≈ $6,311) or INTC at $107.04 (~59 shares ≈ $6,315) within the $6,375.83 max position size — a better asymmetric diversification versus retaining another large lithium stake.
- **Portfolio**: Cash $31,879.15; positions 10/10. Selling 39 ALB (recent trade basis ≈ $1,7177/share → proceeds ≈ $6,699) will reduce positions to 9/10 and raise cash to ≈ $38,578, enabling a new/add-on sized to the 20% per-position cap ($6,375.83) on the next cycle.
- **Historical**: Trade history shows an accumulating pattern: buys on 2026-04-24 (34 @ $188.33) and 2026-06-03 (39 @ $171.77) with an interim sell on 2026-04-30 (34 @ $190.88); current position 39 shares, averageCost reported ≈ $179.48 — indicates recent layering and limited time to prove a durable reflation in lithium.

**Rationale**: Exit Albemarle to reduce commodity concentration and free a slot/cash to rotate into one of the Analyst's asymmetric candidates (gold hedge, LNG, capex or contrarian Intel) — ALB carries oversupply/execution risk despite recent accumulation.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="ALB")`

#### Execution
**Trade**: SELL 39 shares ALB @ $147.22 = $5,741.58 (trade_id 539)

---

### Run 666: Warren (Value Investor)

**Started**: 2026-06-11 05:08:10 UTC | **Completed**: 2026-06-11 05:09:06 UTC
**Status**: COMPLETED

#### Research Phase (30,934 ms)
**Candidates**: CSCO, PG, KO

**Tool Calls** (6):
1. `brave_web_search(query="Cisco CSCO valuation free cash flow ROE P/E 2026 value investor analysis", count=5)`
2. `brave_web_search(query="Procter & Gamble PG valuation ROE P/E free cash flow 2026 value investor analysis", count=5)`
3. `brave_web_search(query="Coca-Cola KO valuation ROE free cash flow P/E 2026 value analysis shareholder friendly buybacks dividend 2026 June", count=5)`
4. `lookup_price_tool(symbol="CSCO")`
5. `lookup_price_tool(symbol="PG")`
6. `lookup_price_tool(symbol="KO")`

**Research Notes**:
> I screened for durable-moat, cash-generative businesses trading at reasonable valuations that complement a nearly-full, dividend-and-quality-oriented portfolio. CSCO (Cisco) offers a wide networking/software moat, very strong free cash flow and ROE (~25% per public stats) with a P/E below some peers — it provides tech exposure distinct from MSFT/ORCL and recent runs show it's been under active consideration. Procter & Gamble (PG) is a classic consumer-staples moat: consistent earnings, high ROE, strong FCF and shareholder-friendly capital allocation (dividends/buybacks) which stabilizes portfolio cyclicality. Coca‑Cola (KO) is another high-quality, cash-generative staple with exceptional ROE and predictable free cash flow and dividends, offering defensive ballast and reliable cash returns.
>
> Collectively these three names increase household & beverage staples exposure (PG, KO) to balance existing tech/industrial/financial holdings and add a cash-rich networking/franchise growth name (CSCO) without overlapping current large positions. Each candidate meets the value-investing emphasis on cash flow, durable competitive advantages, shareholder-friendly management and reasonable valuation metrics based on public statistics cited below.

**Web Sources**:
- [Cisco Systems, Inc. (CSCO) Statistics & Valuation - StockAnalysis](https://stockanalysis.com/stocks/csco/statistics/)
- [Cisco Systems, Inc. (CSCO) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/CSCO/)
- [The Procter & Gamble Company (PG) Statistics & Valuation - StockAnalysis](https://stockanalysis.com/stocks/pg/statistics/)
- [The Procter & Gamble Company (PG) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/PG/)
- [The Coca-Cola Company (KO) Statistics & Valuation - StockAnalysis](https://stockanalysis.com/stocks/ko/statistics/)
- [The Coca-Cola Company (KO) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/KO/)

**Portfolio Context**: Balance $41,573.30, 9 positions (BRK.B, MSFT, JNJ, MCD, ORCL, ADP, MRK, LMT, V).

#### Decision Phase (17,915 ms)
**Decision**: BUY PG x41

**Reasoning**:
- **Research**: Market Analyst candidates: CSCO, PG, KO. PG: trailing P/E ≈21.0, steady FCF and strong shareholder returns. KO: trailing P/E ≈24-25 with ~2.7-2.8% yield — higher multiple and would further increase staples overlap. CSCO: network/software moat with high ROE (~25%) but cited trailing/forward P/E in the mid-to-high-20s and recent account churn, adding execution/cyclicality risk and overlap with existing tech (MSFT/ORCL). Given valuation (PG ≈21 vs KO ≈24-25 and CSCO richer/more cyclical) and our need for defensive, cash-generative ballast, PG is the best fit for a single buy this cycle.
- **Portfolio**: Cash $41,573.30; positions 9/10 — this buy fills the 10th slot. Purchase cost = 41 x $149.05 = $6,111.05, which is <= available cash and <= max position cap $6,235.99, keeping concentration within the 15% limit. Adds defensive staples exposure to complement existing tech/financial/industrial holdings.
- **Historical**: Account trading shows prior PG activity with net accumulation (buys: 41 @ $143.56 on 2026-05-30; prior sells: 23 @ $143.56 on 2026-05-29) — trade history pattern = accumulating, indicating prior conviction and a willingness to hold staples exposure.

**Rationale**: Procter & Gamble (PG) offers a durable consumer-staples moat, predictable free cash flow and shareholder-friendly capital allocation and is trading at a reasonable trailing P/E (~21), providing a margin-of-safety consistent with our long-term value mandate.

**Decision Tool Calls** (3):
1. `get_symbol_trade_history(symbol="CSCO")`
2. `get_symbol_trade_history(symbol="PG")`
3. `get_symbol_trade_history(symbol="KO")`

#### Execution
**Trade**: BUY 41 shares PG @ $149.05 = $6,111.05 (trade_id 537)

---

### Run 667: Cathie (Growth Innovation)

**Started**: 2026-06-11 05:08:10 UTC | **Completed**: 2026-06-11 05:09:51 UTC
**Status**: COMPLETED

#### Research Phase (61,130 ms)
**Candidates**: MBLY, RIVN, COIN, ILMN

**Tool Calls** (8):
1. `brave_web_search(query="Mobileye Q1 2026 revenue beat raised 2026 outlook Mobileye 2026 news Rivian Q1 2026 revenue growth 2026 news Coinbase Q2 2026 results 2026 crypto adoption Illumina 2026 sequencing growth news", count=10)`
2. `brave_web_search(query="Rivian Q1 2026 revenue growth 2026 earnings RIVN autonomy Amazon partnership news 2026", count=10)`
3. `brave_web_search(query="Coinbase Q1 2026 or Q2 2026 results 2026 revenue growth crypto institutional custody adoption 2026 news COIN earnings 2026", count=10)`
4. `brave_web_search(query="Illumina Q1 2026 revenue growth sequencing markets 2026 news Illumina 2026 Rejuvenate growth AI genomics partnerships 2026", count=10)`
5. `lookup_price_tool(symbol="MBLY")`
6. `lookup_price_tool(symbol="RIVN")`
7. `lookup_price_tool(symbol="COIN")`
8. `lookup_price_tool(symbol="ILMN")`

**Research Notes**:
> I screened for disruptive, high-R&D companies that complement Cathie's focus on AI, autonomy, genomics and fintech infrastructure while avoiding existing heavy weights (NVDA, MSFT, GOOGL, ASML, PLTR, etc.). Four candidates emerged: Mobileye (MBLY) — a leader in camera-first ADAS/robotaxi stacks with recent Q1 2026 revenue beat and raised guidance; Rivian (RIVN) — scaling EV production (R2) while investing in autonomy and software-enabled services; Coinbase (COIN) — a crypto infrastructure/marketplace play expanding derivatives, custody and payments; Illumina (ILMN) — genomics/sequencing leader seeing renewed instrument and consumables demand and raised guidance. Each name shows product-led optionality in exponential markets (autonomy, EV software, crypto infrastructure, whole‑genome sequencing) and recent top-line momentum or strategic milestones that could re-accelerate growth.

**Web Sources**:
- [Mobileye reports 27% revenue growth, raises 2026 guidance](https://www.investing.com/news/company-news/mobileye-reports-27-revenue-growth-raises-2026-guidance-93CH-4632029)
- [Did Mobileye's Q1 Beat, Goodwill Hit and Buyback Just Shift It (MBLY)](https://simplywall.st/stocks/us/automobiles/nasdaq-mbly/mobileye-global/news/did-mobileyes-q1-beat-goodwill-hit-and-buyback-just-shift-it)
- [Rivian Releases First Quarter 2026 Financial Results](https://rivian.com/newsroom/article/rivian-releases-first-quarter-2026-financial-results)
- [Rivian's revenue is up as R2 production kicks into gear | The Verge](https://www.theverge.com/transportation/921295/rivian-q1-2026-earnings-revenue-profit-r2)
- [Coinbase Q1 Financial Results Show Resilient Financial Performance](https://investor.coinbase.com/news/news-details/2026/Coinbase-Q1-Financial-Results-Show-Resilient-Financial-Performance-Driven-by-New-All-Time-High-Crypto-Trading-Volume-Market-Share/default.aspx)
- [Coinbase (COIN) earnings Q1 2026 - CNBC](https://www.cnbc.com/2026/05/07/coinbase-coin-earnings-q1-2026.html)
- [Illumina Raises 2026 Guidance on Strong Q1 NovaSeqX Demand](https://www.genomeweb.com/sequencing/illumina-raises-2026-guidance-strong-q1-novaseqx-demand-clinical-consumables-sales)
- [Illumina lifts 2026 outlook on Q1 growth | ILMN 8-K Filing](https://www.stocktitan.net/sec-filings/ILMN/8-k-illumina-inc-reports-material-event-babfbb911902.html)

**Portfolio Context**: Balance $23,862.13, 10 positions (NVDA, DDOG, SNOW, GOOGL, PLTR, ASML, CRWD, MRVL, ARM, MSFT).

#### Decision Phase (33,267 ms)
**Decision**: SELL SNOW x34

**Reasoning**:
- **Research**: Candidates considered: MBLY, RIVN, COIN, ILMN. Mobileye (MBLY) reported ~27% revenue growth and raised 2026 guidance with buyback support — product-led OEM design wins and EyeQ vision stack give clearer near-term commercial optionality and capital efficiency at ~$9-$11 price levels. Rivian (RIVN) is scaling R2 production but remains capex-intensive and execution-sensitive. Coinbase (COIN) is crypto-infrastructure with strong franchise but notable cyclicality and elevated forward/trailing multiples (analyst-cited forward P/E mid-30s to ≈53.9x). Illumina (ILMN) raised 2026 guidance on NovaSeqX demand and consumables strength but is a genomics/instrumentation exposure with different commercial cadence. I prioritize freeing capacity to add MBLY over RIVN/COIN/ILMN because MBLY combines hardware+software autonomy optionality, clearer near-term revenue/guidance momentum and capital efficiency vs the higher capex/execution (RIVN), cyclicality/valuation (COIN), or the different biotech/instrumentation risk profile (ILMN).
- **Portfolio**: Cash $23,862.13; positions 10/10. Holdings include NVDA, DDOG, SNOW (34 sh), GOOGL, PLTR, ASML, CRWD, MRVL, ARM, MSFT. Selling full SNOW position frees one slot and reduces duplicate cloud/data-layer exposure (overlap with GOOGL/MSFT), enabling a future buy of a capital-efficient autonomy/robotics name within the 25% per-position cap.
- **Historical**: Current SNOW: 34 shares, avg cost $173.71; trading pattern shows active accumulating/distribution over past weeks (multiple buys/sells; recent buys at $261.26 and prior sells at $280.16 per internal trade history). I reviewed SNOW trade history to confirm position size and execution cadence (account trade log).

**Rationale**: Reduce thematic overlap with existing cloud/platform holdings and free a slot to redeploy into differentiated autonomy hardware+software exposure (Mobileye) where near-term revenue/guidance momentum is clearer.

**Decision Tool Calls** (2):
1. `get_symbol_trade_history(symbol="MBLY")`
2. `get_symbol_trade_history(symbol="SNOW")`

#### Execution
**Trade**: SELL 34 shares SNOW @ $239.90 = $8,156.60 (trade_id 540)

---

### Run 668: Ray (Risk Parity)

**Started**: 2026-06-11 05:08:10 UTC | **Completed**: 2026-06-11 05:09:10 UTC
**Status**: COMPLETED

#### Research Phase (36,414 ms)
**Candidates**: PG, KO, JNJ

**Tool Calls** (6):
1. `brave_web_search(query="Procter & Gamble (PG) dividend yield beta 2026 site:finance.yahoo.com OR site:morningstar.com OR site:investor.pg.com", count=5)`
2. `brave_web_search(query="Coca-Cola (KO) beta dividend yield 2026 low volatility dividend aristocrat site:finance.yahoo.com OR site:investor.coca-cola.com OR site:morningstar.com", count=5)`
3. `brave_web_search(query="Johnson & Johnson (JNJ) beta dividend yield 2026 low beta dividend aristocrat healthcare defensive site:finance.yahoo.com OR site:morningstar.com OR site:jnj.com", count=5)`
4. `lookup_price_tool(symbol="PG")`
5. `lookup_price_tool(symbol="KO")`
6. `lookup_price_tool(symbol="JNJ")`

**Research Notes**:
> I selected three low-beta, dividend-aristocrat, defensive names that add stable, recession-resistant exposure while avoiding further utility/REIT concentration: Procter & Gamble (PG), Coca‑Cola (KO), and Johnson & Johnson (JNJ). PG and KO are classic consumer-staples compounders with multi-decade dividend growth histories and very low betas (KO notably ~0.3-0.4), which helps stabilize returns in equity drawdowns. JNJ adds broad healthcare/pharma exposure (different from your MDT medical-device tilt) and a long dividend track record, improving portfolio robustness across recession/deflation regimes.
>
> These picks prioritize low correlation and capital preservation: staples and healthcare historically show lower correlation to cyclical sectors and utilities, and their steady payouts support risk-parity income needs. Given the portfolio is near capacity, these are high-conviction, single-name options to consider in small, risk-weighted allocations (1-2 new slots), rather than large concentration bets.

**Web Sources**:
- [The Procter & Gamble Company (PG) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/PG/)
- [PG - Procter and Gamble Dividend History | Morningstar](https://www.morningstar.com/stocks/xnys/pg/dividends)
- [The Coca-Cola Company (KO) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/KO/)
- [Why Coca-Cola and Walmart Top This List of Steady, Low-Volatility Dividend Aristocrats](https://finance.yahoo.com/markets/stocks/articles/why-coca-cola-walmart-top-230002965.html)
- [Johnson & Johnson (JNJ) Stock Price - Yahoo Finance](https://finance.yahoo.com/quote/JNJ/)
- [Stock info - Dividend history | Johnson & Johnson](https://www.investor.jnj.com/stock-info/dividend-history/default.aspx)

**Portfolio Context**: Balance $42,253.98, 9 positions (WM, VZ, ATO, TRV, O, WMT, MDT, DUK, ADP).

#### Decision Phase (16,965 ms)
**Decision**: BUY PG x42

**Reasoning**:
- **Research**: Market Analyst candidates: PG ($149.05; trailing P/E ≈20-21; dividend ≈2.5-3%), KO ($83.59; trailing P/E mid-20s; yield ≈2.7-3%), JNJ ($238.49; trailing P/E ≈22; dividend ≈2.2%). I select PG over KO and JNJ because PG's broader household/product diversification reduces correlation to our heavy industrial/utility/medtech sleeves more than beverage-centric KO, and avoids increasing healthcare concentration with MDT (so JNJ is less attractive). PG's relatively cheaper valuation gives downside cushion while delivering low beta and reliable dividends.
- **Portfolio**: Cash $42,253.98; positions 9/10. Buying 42 PG shares (cost $6,260.10) uses one available slot, keeps total_cost ≤ $6,338.10 per-position cap, and maintains balanced risk-parity allocation by adding a low-correlation defensive staples sleeve.
- **Historical**: Internal trade history shows repeated PG buys/sells over the last 90 days with an accumulating pattern (multiple buys of ~43-46 shares at ~$140-147 and intermittent sells), indicating prior conviction and operational sizing around ~44 shares.

**Rationale**: PG adds low-beta, broad household staples exposure with a lower trailing P/E (≈20-21) and multi-decade dividend growth, improving diversification vs the current industrial/utility/medtech tilt while fitting sizing/cash limits.

**Decision Tool Calls** (1):
1. `get_symbol_trade_history(symbol="PG")`

#### Execution
**Trade**: BUY 42 shares PG @ $149.05 = $6,260.10 (trade_id 538)

---

## Aggregate Statistics — Cycle 665-668

| Metric                                | Value           |
|---------------------------------------|-----------------|
| Total Runs                            | 4               |
| Successful                            | 4 (100%)        |
| Failed                                | 0               |
| Total Trades                          | 4 (2 BUY, 2 SELL) |
| HOLD Decisions                        | 0               |
| Total Capital Deployed (gross)        | $26,269.33      |
| Avg Research Latency                  | 45,018 ms (~45s) |
| Avg Decision Latency                  | 24,684 ms (~25s) |
| Avg Research Tool Calls               | 7.25            |
| Combined Portfolio Value              | $428,189.51     |
| Combined P&L                          | +$28,189.51     |
| Blended Return                        | +7.05%          |
| Reasoning Fields Complete             | 4/4             |
| Missing Phases                        | 0               |
| Guardrail rows populated (V2 audit)   | 8/8 (4 research + 4 decision) |
| Guardrail trips this cycle            | 0               |

---

## Comparison with Previous Report

**Previous**: `TRADING_CYCLE_REPORT_20260610.md` (cycle 06:56 UTC on 2026-06-10, runs 653-656, 4 trades + 0 HOLD)
**Current**: `TRADING_CYCLE_REPORT_20260611.md` (cycle 05:08 UTC on 2026-06-11, runs 665-668, 4 trades + 0 HOLD)

| Metric                          | Previous (653-656)     | Current (665-668)      | Status |
|---------------------------------|------------------------|------------------------|--------|
| Completion Rate                 | 4/4 (100%)             | 4/4 (100%)             | OK     |
| Failed Runs                     | 0                      | 0                      | OK     |
| Trades Executed                 | 4 (2 BUY, 2 SELL)      | 4 (2 BUY, 2 SELL)      | OK     |
| Reasoning Fields Complete       | 4/4                    | 4/4                    | OK     |
| Missing Phases                  | 0                      | 0                      | OK     |
| Avg Research Tool Calls         | 7.75                   | 7.25                   | OK (within normal range) |
| Avg Research Latency            | ~60s                   | ~45s                   | OK (-15s, improvement) |
| Avg Decision Latency            | ~35s                   | ~25s                   | OK (-10s, improvement) |
| Combined Portfolio Value        | $431,853.20            | $428,189.51            | -$3,663.69 (market-dependent) |
| Combined P&L                    | +$31,853.20            | +$28,189.51            | -$3,663.69 (market-dependent) |
| Blended Return                  | +7.96%                 | +7.05%                 | -0.91pp (market-dependent) |
| Guardrail rows populated        | 8/8                    | 8/8                    | OK     |
| Guardrail trips                 | 0                      | 0                      | OK     |
| V2/V3 columns populated correctly | Yes                  | Yes                    | OK     |

### Regressions Found
**None.** All system-level checks passed.

### V2/V3 Guardrail Columns — Populated Correctly?
**Yes.** All 8 phase rows (4 research + 4 decision) for runs 665-668 carry `attempts=1`, `outcome='first_try'`, `issues=NULL`, `failed_output=NULL`. Schema defaults are now baked into the entity layer rather than relying on the manual `ALTER TABLE ... DEFAULT` workaround from the previous deploy; the persistence path through Python → Java DTO → JPA → Postgres remains intact.

### Column-Defaults-Related Backend Log Warnings
Searched `kubectl logs deploy/backend -n agentic-trading-staging --since=1h | grep -iE "default|null|alter table"`. No warnings related to column defaults, NULL violations, or DDL alteration found. The only matches were benign Hibernate boot lines (`PostgreSQLDialect does not need to be specified explicitly` and `spring.jpa.open-in-view is enabled by default`) — neither relates to the schema.

### Style Distribution
- George (Contrarian Macro) — SELL ALB (de-concentrate from lithium overlap)
- Warren (Value Investor) — BUY PG (staples ballast at ~21x trailing)
- Cathie (Growth Innovation) — SELL SNOW (free slot, reduce cloud overlap)
- Ray (Risk Parity) — BUY PG (low-beta defensive sleeve)

---

## Closing Note

**Backend pod health**: `kubectl get pods -n agentic-trading-staging` shows `backend-6757575588-c5ltl` Running 1/1 with 0 restarts (~38m old at report time, consistent with the 04:33 UTC redeploy). `agents`, `frontend`, and `postgres-0` are all Running 1/1.

**Grafana V4/V5 status**: Both ConfigMaps are loaded in the `monitoring` namespace.
- `grafana-dashboards` carries the guardrail panels (`Guardrail Trip Rate by Event Type`, `Guardrail Trips by Agent`, `Recent Guardrail Exhausted Events`) inside a "Guardrails" row. **Important caveat**: the V4 panels landed in the existing `logs-explorer.json` dashboard, not in a standalone `trading-dashboard.json` — there is no separate trading dashboard ConfigMap key. The implementer's note checks out.
- `grafana-alert-rules` carries the V5 alert rule `guardrail_exhausted_rate_high` (uid `guardrail-exhausted-rate-high`) in the `guardrails` group, configured to fire when `sum(rate({app=~"agents.*"} | json | event_type="guardrail_exhausted" [10m])) > 0.1/sec` for a sustained 10m window.

**Trading dashboard URL**: Accessible at https://grafana.vkontech.com/d/logs-explorer/logs-explorer. The path `/d/logs-explorer/...` resolves to the dashboard that now hosts the guardrail panels — flagged here so a future viewer is not surprised to find guardrail observability under the "logs-explorer" name rather than a "trading-dashboard" name.
